Problem: Preeclampsia, a pregnancy-related hypertensive disorder, is one of the leading causes of fetal and maternal death globally. Angiogenic factors including vascular endothelial growth factor (VEGF) are involved in the formation of new blood vessels required for placental development and function. The hallmark of preeclampsia is similar to the toxicities related to antiangiogenesis therapy. VEGF inhibitors or antagonists promote vasoconstriction, hypertension and proteinuria. VEGF plays a role in attenuating hypertension and improving kidney damage in an animal model; however, the mechanisms underlying this effect remain poorly defined. The aim of this paper is to summarize recent advances in VEGF-mediated signaling and the target molecules, and provide new insights into treatment strategies for preeclampsia. Method of Study: This article reviews the English-language literature for pathogenesis of preeclampsia based on VEGF signaling and hypertension. Results: VEGF activates downstream signaling molecules, including Ca2+/CAMKK, Rac1/NOX, ROS/ERK, Ezrin/Calpain/PI3K/Akt, PLCγ/PKC and Src/HSP90. Among these signalings, important pathways for receptor-triggered intracellular signaling are (1) the PI3K/Akt-dependent, (2) the PLCγ-dependent and (3) the ERK/Egr-1-dependent pathway. VEGF is closely involved in receptor-activated signaling events, leading to eNOS-dependent NO synthesis and eNOS-independent endothelial cell proliferation, respectively, and thus modulates vasoactive function and angiogenic response. Conclusion: This review highlights the potential role of NO in vasodilation, while stress-related ERK activation might act to strengthen angiogenesis, migration and proliferation. We discuss the similarity between preeclampsia and VEGF-targeted therapy-induced hypertension.

Keywords:
Vascular endothelial growth factor, Angiogenesis, Nitric oxide, Vasodilation, Hypertension, Preeclampsia
1.
Tanbe AF, Khalil RA: Circulating and vascular bioactive factors during hypertension in pregnancy. Curr Bioact Compd 2010;6:60–75.
2.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649–658.
3.
Yang F, Jin C, Jiang YJ, Li J, Di Y, Fu DL: Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer. Expert Rev Anticancer Ther 2011;11:541–549.
4.
Leite de Oliveira R, Hamm A, Mazzone M: Growing tumor vessels: more than one way to skin a cat – implications for angiogenesis targeted cancer therapies. Mol Aspects Med 2011;32:71–87.
5.
Masuyama H, Segawa T, Sumida Y, Masumoto A, Inoue S, Akahori Y, Hiramatsu Y. Different profiles of circulating angiogenic factors and adipocytokines between early- and late-onset pre-eclampsia. BJOG 2010;117:314–320.
6.
Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006;203:2165–2175.
7.
Mourad JJ, des Guetz G, Debbabi H, Levy BI: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008;19:927–934.
8.
Robinson ES, Khankin EV, Choueiri TK, Dhawan MS, Rogers MJ, Karumanchi SA, Humphreys BD: Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010;56:1131–1136.
9.
Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K: Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011;25:159–169.
10.
Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Grantham J: Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol 2009;7:79.
11.
Negro R: Endothelial effects of antihypertensive treatment: focus on irbesartan. Vasc Health Risk Manag 2008;4:89–101.
12.
Gao Y: The multiple actions of NO. Pflugers Arch 2010;459:829–839.
13.
Brown GC: Nitric oxide and neuronal death. Nitric Oxide 2010;23:153–165.
14.
Gryglewski RJ: Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t-PA): alliance or neutrality? Pol J Pharmacol 1995;47:467–472.
15.
Lai YJ, Pullamsetti SS, Dony E, Weissmann N, Butrous G, Banat GA, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT: Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am J Respir Crit Care Med 2008;178:188–196.
16.
Gryglewski RJ: Prostacyclin among prostanoids. Pharmacol Rep 2008;60:3–11.
17.
Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH: Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:1161–1170.
18.
Tsai MC, Chen L, Zhou J, Tang Z, Hsu TF, Wang Y, Shih YT, Peng HH, Wang N, Guan Y, Chien S, Chiu JJ: Shear stress induces synthetic-to-contractile phenotypic modulation in smooth muscle cells via peroxisome proliferator-activated receptor alpha/delta activations by prostacyclin released by sheared endothelial cells. Circ Res 2009;105:471–480.
19.
Katada J, Majima M: AT2 receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. Br J Pharmacol 2002;136:484–491.
20.
Valdés G, Chacón C, Corthorn J, Figueroa CD, Germain AM: Tissue kallikrein in human placenta in early and late gestation. Endocrine 2001;14:197–204.
21.
Bhatt DK, Ploug KB, Ramachandran R, Olesen J, Gupta S: Activation of PAR-2 elicits NO-dependent and CGRP-independent dilation of the dural artery. Headache 2010;50:1017–1030.
22.
Stewart JM, Ocon AJ, Clarke D, Taneja I, Medow MS: Defects in cutaneous angiotensin-converting enzyme 2 and angiotensin-(1–7) production in postural tachycardia syndrome. Hypertension 2009;53:767–774.
23.
Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, Levitt KS, Oudit GY, Al-Omran M, Stewart DJ, Slutsky AS, Peterson MD, Backx PH, Penninger JM, Verma S: Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol 2008;295:H1377–H1384.
24.
Bani D: Relaxin as a natural agent for vascular health. Vasc Health Risk Manag 2008;4:515–524.
25.
Gien J, Seedorf GJ, Balasubramaniam V, Markham N, Abman SH: Intrauterine pulmonary hypertension impairs angiogenesis in vitro: role of vascular endothelial growth factor nitric oxide signaling. Am J Respir Crit Care Med 2007;176:1146–1153.
26.
Duval M, Le Boeuf F, Huot J, Gratton JP: Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell 2007;18:4659–4668.
27.
Youn JY, Wang T, Cai H: An ezrin/calpain/PI3K/AMPK/eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. Circ Res 2009;104:50–59.
28.
Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM: Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652–658.
29.
Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611.
30.
Vyzantiadis T, Karagiannis A, Douma S, Harsoulis P, Vyzantiadis A, Zamboulis C: Vascular endothelial growth factor and nitric oxide serum levels in arterial hypertension. Clin Exp Hypertens 2006;28:603–609.
31.
Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, Ledda F, Ziche M: Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem 1998;273:4220–4226.
32.
Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1999;99:2625–2634.
33.
Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M: Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996;270:H411–H415.
34.
Khazaei M, Nematbakhsh M: The effect of hypertension on serum nitric oxide and vascular endothelial growth factor concentrations. A study in DOCA-Salt hypertensive ovariectomized rats. Regul Pept 2006;135:91–94.
35.
Bates DO: Vascular endothelial growth factors and vascular permeability. Cardiovasc Res 2010;87:262–271.
36.
Dvorak HF: Vascular permeability to plasma, plasma proteins, and cells: an update. Curr Opin Hematol 2010;17:225–229.
37.
Hood JD, Meininger CJ, Ziche M, Granger HJ: VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054–H1058.
38.
Cindrova-Davies T, Sanders DA, Burton GJ, Charnock-Jones DS: Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res 2011;89:671–679.
39.
Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999;399:601–605.
40.
Leloup L, Shao H, Bae YH, Deasy B, Stolz D, Roy P, Wells A: m-Calpain activation is regulated by its membrane localization and by its binding to phosphatidylinositol 4,5-bisphosphate. J Biol Chem 2010;285:33549–33566.
41.
Wang F, Xia P, Wu F, Wang D, Wang W, Ward T, Liu Y, Aikhionbare F, Guo Z, Powell M, Liu B, Bi F, Shaw A, Zhu Z, Elmoselhi A, Fan D, Cover TL, Ding X, Yao X: Helicobacter pylori VacA disrupts apical membrane-cytoskeletal interactions in gastric parietal cells. J Biol Chem 2008;283:26714–26725.
42.
Su Y, Cui Z, Li Z, Block ER: Calpain-2 regulation of VEGF-mediated angiogenesis. FASEB J 2006;20:1443–1451.
43.
Chandra A, Angle N: Vascular endothelial growth factor stimulates a novel calcium-signaling pathway in vascular smooth muscle cells. Surgery 2005;138:780–787.
44.
Neal AP, Molina-Campos E, Marrero-Rosado B, Bradford AB, Fox SM, Kovalova N, Hannon HE: CaMKK-CaMKI signaling pathways differentially control axon and dendrite elongation in cortical neurons. J Neurosci 2010;30:2807–2809.
45.
Stahmann N, Woods A, Spengler K, Heslegrave A, Bauer R, Krause S, Viollet B, Carling D, Heller R: Activation of AMP-activated protein kinase by vascular endothelial growth factor mediates endothelial angiogenesis independently of nitric-oxide synthase. J Biol Chem 2010;285:10638–10652.
46.
Thomson DM, Winder WW: AMP-activated protein kinase control of fat metabolism in skeletal muscle. Acta Physiol (Oxf) 2009;196:147–154.
47.
Reihill JA, Ewart MA, Salt IP: The role of AMP-activated protein kinase in the functional effects of vascular endothelial growth factor-A and -B in human aortic endothelial cells. Vasc Cell 2011;3:9.
48.
Ford RJ, Rush JW: Endothelium-dependent vasorelaxation to the AMPK activator AICAR is enhanced in aorta from hypertensive rats and is NO and EDCF dependent. Am J Physiol Heart Circ Physiol 2011;300:H64–H75.
49.
Levine YC, Li GK, Michel T: Agonist-modulated regulation of AMP-activated protein kinase (AMPK) in endothelial cells. Evidence for an AMPK -> Rac1 -> Akt -> endothelial nitric-oxide synthase pathway. J Biol Chem 2007;282:20351–20364.
50.
Nakagawa T, Sato W, Sautin YY, Glushakova O, Croker B, Atkinson MA, Tisher CC, Johnson RJ: Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. J Am Soc Nephrol 2006;17:736–745.
51.
Rask-Madsen C, King GL: Differential regulation of VEGF signaling by PKC-alpha and PKC-epsilon in endothelial cells. Arterioscler Thromb Vasc Biol 2008;28:919–924.
52.
Beckers CM, van Hinsbergh VW, van Nieuw Amerongen GP: Driving Rho GTPase activity in endothelial cells regulates barrier integrity. Thromb Haemost 2010;103:40–55.
53.
Li SM, Zeng LW, Feng L, Chen DB: Rac1-dependent intracellular superoxide formation mediates vascular endothelial growth factor-induced placental angiogenesis in vitro. Endocrinol 2010;151:5315–5325.
54.
Zhuang J, Jiang T, Lu D, Luo Y, Zheng C, Feng J, Yang D, Chen C, Yan X: NADPH oxidase 4 mediates reactive oxygen species induction of CD146 dimerization in VEGF signal transduction. Free Radic Biol Med 2010;49:227–236.
55.
Ushio-Fukai M, Nakamura Y: Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 2008;266:37–52.
56.
Ago T, Kuroda J, Kamouchi M, Sadoshima J, Kitazono T: Pathophysiological roles of NADPH oxidase/nox family proteins in the vascular system. Circ J 2011;75:1791–1800.
57.
Monaghan-Benson E, Hartmann J, Vendrov AE, Budd S, Byfield G, Parker A, Ahmad F, Huang W, Runge M, Burridge K, Madamanchi N, Hartnett ME: The role of vascular endothelial growth factor-induced activation of NADPH oxidase in choroidal endothelial cells and choroidal neovascularization. Am J Pathol 2010;177:2091–2102.
58.
Schweighofer B, Schultes J, Pomyje J, Hofer E: Signals and genes induced by angiogenic growth factors in comparison to inflammatory cytokines in endothelial cells. Clin Hemorheol Microcirc 2007;37:57–62.
59.
Khachigian LM: Early growth response-1: blocking angiogenesis by shooting the messenger. Cell Cycle 2004;3:10–11.
60.
Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999;4:915–924.
61.
Hayashi H, Nakagami H, Takami Y, Koriyama H, Mori M, Tamai K, Sun J, Nagao K, Morishita R, Kaneda Y: FHL-2 suppresses VEGF-induced phosphatidylinositol 3-kinase/Akt activation via interaction with sphingosine kinase-1. Arterioscler Thromb Vasc Biol 2009;29:909–914.
62.
Thachil J: Nitric oxide and adverse events of vascular endothelial growth factor inhibitors. Curr Med Res Opin 2011;27:1503–1507.
63.
Shibuya M: Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 2008;41:278–286.
64.
Puzzo D, Sapienza S, Arancio O, Palmeri A: Role of phosphodiesterase 5 in synaptic plasticity and memory. Neuropsychiatr Dis Treat 2008;4:371–387.
65.
Downing JW, Ramasubramanian R, Johnson RF, Minzter BH, Paschall RL, Sundell HW, Engelhardt B, Lewis R: Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia. Med Hypotheses 2004;63:1057–1064.
66.
Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B: The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. Eur J Pharmacol 2008;589:180–187.
67.
Wareing M, Myers JE, O’hara M, Kenny LC, Warren AY, Taggart MJ, Skillern L, Machin I, Baker PN: Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. Am J Obstet Gynecol 2004;190:1283–1290.
68.
Wareing M, Myers JE, O’Hara M, Kenny LC, Taggart MJ, Skillern L, Machin I, Baker PN: Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2006;127:41–49.
69.
Samangaya RA, Mires G, Shennan A, Skillern L, Howe D, McLeod A, Baker PN: A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:369–382.
70.
Brownbill P, McKeeman GC, Brockelsby JC, Crocker IP, Sibley CP: Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. Endocrinol 2007;148:4734–4744.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.